119 related articles for article (PubMed ID: 27055128)
1. Fibrous Dysplasia Presenting as a Cold Spot in 18F-FLT PET/CT Imaging.
Rehak Z; Bencsikova B; Zambo I; Kazda T
Clin Nucl Med; 2016 Jun; 41(6):510-1. PubMed ID: 27055128
[TBL] [Abstract][Full Text] [Related]
2. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
4. 18 F-FDG avid lesion due to coexistent fibrous dysplasia in a child of embryonal rhabdomyosarcoma: source of false positive FDG-PET.
Basu S; Baghel NS; Puri A; Shet T; Merchant NH
J Cancer Res Ther; 2010; 6(1):92-4. PubMed ID: 20479556
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
6. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
7. F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones.
Berrebi O; Steiner C; Keller A; Rougemont AL; Ratib O
Clin Nucl Med; 2008 Jul; 33(7):469-71. PubMed ID: 18580231
[TBL] [Abstract][Full Text] [Related]
8. Current clinical status of
Nakajo M; Kajiya Y; Jinguji M; Nakabeppu Y; Nakajo M; Nihara T; Yoshiura T
Abdom Radiol (NY); 2017 Mar; 42(3):951-961. PubMed ID: 27770160
[TBL] [Abstract][Full Text] [Related]
9. Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT.
Papadakis GZ; Millo C; Sadowski SM; Karantanas AH; Bagci U; Patronas NJ
Clin Nucl Med; 2017 Mar; 42(3):209-210. PubMed ID: 28072620
[TBL] [Abstract][Full Text] [Related]
10. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
12. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
[TBL] [Abstract][Full Text] [Related]
14. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
16. Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease.
Bonekamp D; Jacene H; Bartelt D; Aygun N
Clin Nucl Med; 2008 Dec; 33(12):909-11. PubMed ID: 19033807
[TBL] [Abstract][Full Text] [Related]
17. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
Lu L; Jiang L; Guan H; Gao Y; Lu H
Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
[TBL] [Abstract][Full Text] [Related]
18. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
[TBL] [Abstract][Full Text] [Related]
19. The appearance of Mazabraud's syndrome on 18F-FDG PET/CT.
Singnurkar A; Phancao JP; Chatha DS; Stern J
Skeletal Radiol; 2007 Nov; 36(11):1085-9. PubMed ID: 17589842
[TBL] [Abstract][Full Text] [Related]
20. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
